Elevance Health President and CEO Gail Boudreaux bought 680 shares in the open market on July 17, 2026, paying $366.41 per share for a total outlay of about $249,160. CEO purchases are closely watched because they represent a top decision-maker increasing personal exposure to the company’s stock, rather than receiving shares through compensation. This trade matters because open-market buys typically involve an insider choosing to commit personal capital at prevailing prices. As CEO, Boudreaux has broad visibility into the business, strategy, and operating environment, so her decision to add shares can be viewed as a notable vote of alignment with shareholders. The filing indicates this was a purchase rather than an automatic sale, which is generally less common among executives. The buy also occurred alongside another insider purchase the same day: Ramiro G. Peru bought about $366,050 worth of ELV shares. Two separate insider purchases in a single day can be a meaningful data point for investors tracking insider sentiment, though it remains just one input among fundamentals, valuation, and broader health insurance industry conditions.